Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH

Single-agent vemurafenib leads to a rapid and sustained clinical response in severe multisystem LCH but does not eradicate the disease. Longitudinal assessment of BRAF V600E during treatment shows that clinical remission can occur despite significant amounts of mutated BRAF.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Kolenová, Alexandra, Schwentner, Raphaela, Jug, Gunhild, Simonitsch-Klupp, Ingrid, Kornauth, Christoph, Plank, Lukáš, Horáková, Júlia, Bodová, Ivana, Sýkora, Tomáš, Geczová, Lucia, Holter, Wolfgang, Minkov, Milen, Hutter, Caroline
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2017
Konular:
Exceptional Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738993/
https://ncbi.nlm.nih.gov/pubmed/29296950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003533
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller